Mutations in TP53 encoding p53, while not as prevalent as in solid tumors, have been identified in approximately 20–30% of patients with lymphoid malignancies including lymphomas and appear to be a prognostic indicator predicting inferior survival [43], [44]. This evidence concerns the gene TP53 and lymphoma.